Analyst Forecasts $5bn Sales For Moderna Vaccine – But Much Still Hangs In The Balance
Bullish Outlook From Jefferies
COVID-19 success could catapult Moderna into the same biotech breakthrough realm as Regeneron and Vertex, but the accelerated venture remains risky.
